Marron Thomas U, Ronner Lukas, Martin Peter E, Flowers Christopher R, Brody Joshua D
Division of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medical College, New York, NY, USA.
Immunotherapy. 2016 Nov;8(11):1335-1346. doi: 10.2217/imt-2016-0080.
The clonal B-cell immunoglobulin idiotype found on the surface of lymphomas was the first targeted tumor-specific antigen, and combinations of idiotype with classical and novel adjuvants were shown to stimulate robust humoral and cellular responses, though clinical efficacy was more variable. Cellular and in situ vaccination to help target a wider array of tumor-specific antigens have also been able to stimulate tumor-specific cellular responses, though their clinical success has also been limited. Our growing understanding of the role of regulatory cells and the immunosuppressive tumor microenvironment, along with a wide variety of immunomodulatory agents developed as of late, offer promising adjuvants to potentiate the immune responses elicited by these vaccine protocols and to achieve durable remissions.
淋巴瘤表面发现的克隆性B细胞免疫球蛋白独特型是首个靶向肿瘤特异性抗原，独特型与传统及新型佐剂的组合已显示可刺激强烈的体液和细胞反应，尽管临床疗效更具变异性。细胞和原位疫苗接种有助于靶向更广泛的肿瘤特异性抗原，也能够刺激肿瘤特异性细胞反应，但其临床成功同样有限。我们对调节性细胞和免疫抑制性肿瘤微环境作用的认识不断加深，以及近期开发的多种免疫调节剂，为增强这些疫苗方案引发的免疫反应并实现持久缓解提供了有前景的佐剂。
